Impact of Clinicopathologic Factors on Breast Cancer Diagnosed in Pregnancy
- 1Department of Internal Medicine, University of Texas Southwestern, Dallas, TX, USA
Abstract
Introduction: Effective management of breast cancer diagnosed during pregnancy (PrBC) requires the coordination of multiple specialists, including maternal-fetal medicine (MFM) specialists and medical oncologists, as patients often present at a younger age with more aggressive tumor biology. It is critical to evaluate how increased time from diagnosis to treatment initiation may impact development of pregnancy complications and maternal survival outcomes.
Methods: A retrospective study was conducted to evaluate all female patients who were diagnosed with breast cancer during pregnancy across a safety-net hospital and private comprehensive cancer center from January 2015 to December 2024. Event-free survival (EFS) and overall survival (OS) were analyzed using Cox proportional hazards models adjusting for covariates including initiation of treatment during pregnancy.
Results: Among 34 patients with PrBC, 20 (58.8%) patients received chemotherapy during pregnancy, and 19 (55.8%) patients experienced maternal or fetal complications during pregnancy. Twelve patients (35.3%) were diagnosed with stage III breast cancer, and 8 patients (23.5%) were diagnosed with stage IV disease. Patients who experienced complications of pregnancy also experienced increased time between initial biopsy and establishment with MFM compared to those without complications (p = 0.03). There were no significant differences in EFS and OS among patients who did and did not initiate treatment during pregnancy, nor was increased time from breast cancer diagnosis to systemic treatment initiation associated with worsened EFS or OS. Stage III and IV breast cancer diagnosis (hazard ratios [HRs]: 9.79; 95% confidence interval [CI], 1.30–76.9; p = 0.03) was associated with worsened EFS; increased BMI at diagnosis was also associated with worsened OS (HR: 1.30; 95% CI, 1.05–1.62; p = 0.02).
Conclusion: While initiation of antenatal chemotherapy was not associated with improved patient outcomes, clinicopathologic factors – including advanced disease staging and increased BMI – may impact survival in PrBC. Establishment of a dedicated interdisciplinary team may improve coordination of multidisciplinary care and optimize outcomes within PrBC care.
Related
- Clinicopathologic features and prognostic factors of breast cancer brain metastases patients based on molecular subtypes: a real-world retrospective analysis
- Sociodemographic and clinicopathologic features associated with rapid relapse in triple-negative breast cancer: a Swedish nationwide registry-based study.
- Re: Research Article: Emotional Reactivity and Regulation Relate to Surgical Treatment Decision Making Among Newly Diagnosed Women With Breast Cancer
- Association between thyroid hormone sensitivity indices and surrogate clinicopathologic subtypes of breast cancer : A retrospective single-center study
- Prognostic Impact of EASIX According to the Timing of Assessment in Newly Diagnosed Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
BibTeX
@article{su2026impact,
title = {{Impact of Clinicopathologic Factors on Breast Cancer Diagnosed in Pregnancy}},
author = {Malcolm Su and Diti Patel and Samira Syed and Glenda Delgado Ramos and Heather McArthur and Ina Patel and Poorni Manohar and Shifa Kanjwal},
journal = {Oncology},
year = {2026},
month = sep,
doi = {10.1159/ocl/aebag014},
url = {https://doi.org/10.1159/ocl/aebag014},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Impact of Clinicopathologic Factors on Breast Cancer Diagnosed in Pregnancy
AU - Malcolm Su
AU - Diti Patel
AU - Samira Syed
AU - Glenda Delgado Ramos
AU - Heather McArthur
AU - Ina Patel
AU - Poorni Manohar
AU - Shifa Kanjwal
PY - 2026
DA - 2026/09/22
JO - Oncology
DO - 10.1159/ocl/aebag014
UR - https://doi.org/10.1159/ocl/aebag014
AB - Introduction: Effective management of breast cancer diagnosed during pregnancy (PrBC) requires the coordination of multiple specialists, including maternal-fetal medicine (MFM) specialists and medical oncologists, as patients often present at a younger age with more aggressive tumor biology. It is critical to evaluate how increased time from diagnosis to treatment initiation may impact development of pregnancy complications and maternal survival outcomes. Methods: A retrospective study was conducted to evaluate all female patients who were diagnosed with breast cancer during pregnancy across a safety-net hospital and private comprehensive cancer center from January 2015 to December 2024. Event-free survival (EFS) and overall survival (OS) were analyzed using Cox proportional hazards models adjusting for covariates including initiation of treatment during pregnancy. Results: Among 34 patients with PrBC, 20 (58.8%) patients received chemotherapy during pregnancy, and 19 (55.8%) patients experienced maternal or fetal complications during pregnancy. Twelve patients (35.3%) were diagnosed with stage III breast cancer, and 8 patients (23.5%) were diagnosed with stage IV disease. Patients who experienced complications of pregnancy also experienced increased time between initial biopsy and establishment with MFM compared to those without complications (p = 0.03). There were no significant differences in EFS and OS among patients who did and did not initiate treatment during pregnancy, nor was increased time from breast cancer diagnosis to systemic treatment initiation associated with worsened EFS or OS. Stage III and IV breast cancer diagnosis (hazard ratios [HRs]: 9.79; 95% confidence interval [CI], 1.30–76.9; p = 0.03) was associated with worsened EFS; increased BMI at diagnosis was also associated with worsened OS (HR: 1.30; 95% CI, 1.05–1.62; p = 0.02). Conclusion: While initiation of antenatal chemotherapy was not associated with improved patient outcomes, clinicopathologic factors – including advanced disease staging and increased BMI – may impact survival in PrBC. Establishment of a dedicated interdisciplinary team may improve coordination of multidisciplinary care and optimize outcomes within PrBC care.
SN - 0030-2414
SN - 1423-0232
ER -